Related Experiment Video
Updated: Oct 23, 2025

Author Spotlight: Validating Cancer Therapy Responses with Desmoplastic Spheroid Models
Published on: September 27, 2024
Nrf2 expression in pancreatic stellate cells promotes progression of cancer
Yu Tanaka1, Shin Hamada1, Ryotaro Matsumoto1
1Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Abstract:
It was previously identified that systemic Nrf2 deletion attenuates pancreatic cancer progression in a mutant K-ras/p53-expressing mouse model (KPC mouse). In this study, the type of cell that is responsible for the retarded cancer progression was elucidated. Human pancreatic cancers were first examined, and elevated expression of NRF2-target gene products in α-smooth muscle actin-positive cells was found, suggesting that pancreatic stellate cells (PSCs) are involved in this process. Closer examination of primary cultured PSCs from Nrf2-deleted mice revealed that the cells were less proliferative and retained a lower migration capacity. The conditioned medium of Nrf2-deleted PSCs exhibited reduced growth-stimulating effects in pancreatic cancer cells. KPC mouse-derived pancreatic cancer cells coinjected with wild-type PSCs developed significantly larger subcutaneous tumors in immunodeficient mice than those coinjected with Nrf2-deleted PSCs. These results demonstrate that Nrf2 actively contributes to the function of PSCs to sustain KPC cancer progression, thus, suggesting that Nrf2 inhibition in PSCs may be therapeutically important in pancreatic cancer.NEW & NOTEWORTHY This study identified that Nrf2 contributes to PSC activation. Nrf2 deletion in PSCs resulted in attenuation of cancer-promoting role. Nrf2 in PSCs could be an attractive therapeutic target in pancreatic cancer.
Insights
Nuclear factor erythroid 2-related factor 2 (Nrf2) promotes pancreatic stellate cell (PSC) activation, which drives pancreatic ductal adenocarcinoma progression. Inhibiting Nrf2 in PSCs may offer a novel therapeutic strategy for pancreatic cancer.
Area of Science:
- Oncology
- Cell Biology
- Cancer Research
Background:
- Systemic Nrf2 deletion was previously shown to slow pancreatic cancer growth in KPC mice.
- The specific cell type mediating this effect remained unclear.
Purpose of the Study:
- To identify the cell type responsible for Nrf2-mediated pancreatic cancer progression.
- To investigate the role of Nrf2 in pancreatic stellate cells (PSCs) and their contribution to pancreatic cancer.
Main Methods:
- Examined human pancreatic cancers for NRF2-target gene expression in α-smooth muscle actin-positive cells.
- Cultured PSCs from Nrf2-deleted mice and assessed proliferation and migration.
- Evaluated the effect of conditioned medium from Nrf2-deleted PSCs on pancreatic cancer cells.
- Coinjected KPC mouse-derived cancer cells with wild-type or Nrf2-deleted PSCs in immunodeficient mice.
Main Results:
- Elevated NRF2-target gene products were found in PSCs of human pancreatic cancers.
- Nrf2-deleted PSCs exhibited reduced proliferation and migration.
- Conditioned medium from Nrf2-deleted PSCs had diminished growth-stimulating effects on cancer cells.
- Tumor growth was significantly smaller when cancer cells were coinjected with Nrf2-deleted PSCs compared to wild-type PSCs.
Conclusions:
- Nrf2 actively promotes PSC function, sustaining KPC pancreatic cancer progression.
- Nrf2 in PSCs is a potential therapeutic target for pancreatic cancer treatment.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
The Ras Gene
Ras is a...
Induced Pluripotent Stem Cells
Somatic...
Psychoneuroimmunology: Diabetes and Cancer

